ClinicalTrials.gg
Sign In

Breast Neoplasms, Male clinical trials

The registry lists 286 studies for Breast Neoplasms, Male across more than 10 countries. 5 are recruiting or about to start. 94 of them are mainly about Breast Neoplasms, Male (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-13.

Get an email when these change. Save the Breast Neoplasms, Male studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
202
Terminated
43
Status unknown
19
Withdrawn
10
Active, not recruiting
7
Recruiting
5

Phase

Phase 2
131
Phase 1
97
Phase 3
20
Early Phase 1
5

Where

United States
234
Canada
15
United Kingdom
12
France
9
Switzerland
6
Germany
6

Who runs them

National Cancer Institute (NCI) (57) · Alliance for Clinical Trials in Oncology (17) · University of Washington (17) · Memorial Sloan Kettering Cancer Center (9) · Case Comprehensive Cancer Center (8) · H. Lee Moffitt Cancer Center and Research Institute (7) · City of Hope Medical Center (7) · SWOG Cancer Research Network (6)

What is being tested here

Drugs under test in Breast Neoplasms, Male studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Anastrozole103
Tamoxifen112
Degarelix101
Abemaciclib101
Paclitaxel0120
Cyclophosphamide0219
Docetaxel0015
Trastuzumab0114
Doxorubicin0214
Bevacizumab0212

Drug classes tested here Aromatase inhibitors 1 open · Antimitotic agents 47 · Tyrosine kinase inhibitors (TKIs) 34 · Antimetabolites 23 · Alkylating agents 22

Coming up

4phase 3 studies under way
4studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 4

Who these studies take

Of the 5 Breast Neoplasms, Male studies recruiting now, 5 (100%) set no upper age limit and 0 (0%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 3 (60%) for men only; 1 (20%) take healthy volunteers.

Recruiting studies that take each age, of 5
AgeWomenMen
100 (0%)0 (0%)
182 (40%)4 (80%)
302 (40%)4 (80%)
402 (40%)4 (80%)
502 (40%)4 (80%)
652 (40%)4 (80%)
752 (40%)5 (100%)
852 (40%)5 (100%)

Across all 286 studies, recruiting or not: 3% stop at 75 or younger and 2% at 65; 7% take children; 2% are for women only and 5% for men only; 1% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Breast Neoplasms, Male studies take

Of 20 phase 2 interventional studies under Breast Neoplasms, Male, half reached primary completion within 49 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 144 mo20–54 · 15 studies——
Phase 249 mo25–75 · 20 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 15, 2026.

Started recruiting1

Studies

Recruiting first, then most recently updated. Showing 50 of 286. Browse all 286 → or search them.